TrialInvestigational new drugs2015

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.

Suzanne Leijen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.